Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Review
DOI: 10.54448/ijn22208
Submitted: 25-05-2022
Published: 25-05-2022

Major clinical outcomes of melatonin use in COVID-19 patients: a systematic review

UNILAGO - Uniao Das Faculdades Dos Grandes Lagos - Medical School, Sao Jose do Rio Preto/SP, Brazil
FUNFARME - Base Hospital, Anesthesia Department, Sao Jose do Rio Preto, Sao Paulo, Brazil
Melatonin Immunomodulation Inflammatory process SARS-CoV-2 COVID-19 Clinical trials

Abstract

Introduction: In the context of the Sars-Cov-2 (COVID-19) pandemic, as well as other viral infections, these viruses can lead to significant morbidity and mortality. Thus, in the context of melatonin science in viral infections such as influenza and COVID-19, there is a growing realization that the regulation of melatonin pathways, both pineal and systemic, may be an important aspect of the regulation of viruses in cellular functions. Objective: It was to list the main results of clinical studies of the use of melatonin in patients infected with Sars-Cov-2 through a systematic review. Methods: The rules of the Systematic Review-PRISMA Platform. The search was carried out from December 2021 to April 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: It was found 164 articles. A total of 86 articles were fully evaluated and 30 studies were developed in a systematic review. Melatonin is known as an anti-inflammatory agent and immune modulator that may address the progressive pathophysiology of coronavirus disease 2019 (COVID-19). According to the objective and results obtained in the present study that evaluated the treatment in patients with COVID-19, the use of melatonin can help reduce thrombosis, sepsis and mortality. Furthermore, the combination of 3.0 mg oral melatonin tablets and standard care can substantially improve sleep quality and blood oxygen saturation in hospitalized patients. Clinical symptoms such as cough, dyspnea and fatigue, as well as the polymerase chain reaction (PCR) level and lung involvement in patients receiving melatonin can improve significantly. Also, the mean time of patients' hospital discharge and return to initial health was significantly shorter in patients who received melatonin compared to the control group. There was evidence of benefit of sustained-release melatonin 2 mg in therapy in patients, as well as evidence that the use of melatonin was associated with a reduced probability of a positive SARS-CoV-2 test result compared to the use of blockers of the angiotensin II receptor or angiotensin-converting enzyme inhibitors.

Metrics

Metrics Loading ...

References

  1. Bahrampour Juybari K, Pourhanifeh MH, Hosseinzadeh A, Hemati K, Mehrzadi S. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Virus Res. 2020 Oct 2;287:198108. doi: 10.1016/j.virusres.2020.198108. Epub 2020 Aug 5. PMID: 32768490; PMCID: PMC7405774.
  2. Amaral FGD, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab. 2018 Aug;62(4):472-479. doi: 10.20945/2359-3997000000066. PMID: 30304113.
  3. Cipolla‐Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56(4):371‐381.
  4. Cipolla-Neto J, Amaral FGD. Melatonin as a Hormone: New Physiological and Clinical Insights. Endocr Rev. 2018;39(6):990–1028. doi:10.1210/er.2018-00084.
  5. Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015 Apr-Jun;61(2-3):77-84. doi: 10.1016/j.neuchi.2015.03.002. Epub 2015 Apr 20. PMID: 25908646.
  6. Farias, T., Paixao, R., Cruz, M. M., de Sa, R., Simão, J. J., Antraco, V. J., & Alonso-Vale, M. (2019). Melatonin Supplementation Attenuates the Pro-Inflammatory Adipokines Expression in Visceral Fat from Obese Mice Induced by A High-Fat Diet. Cells, 8(9), 1041. https://doi.org/10.3390/cells8091041.
  7. Mayo JC, Aguado A, Cernuda-Cernuda R, Álvarez-Artime A, Cepas V, Quirós-González I, Hevia D, Sáinz RM. Melatonin Uptake by Cells: An Answer to Its Relationship with Glucose? Molecules. 2018 Aug 10;23(8):1999. doi: 10.3390/molecules23081999. PMID: 30103453; PMCID: PMC6222335.
  8. Czuczejko J, Sielski Ł, Woźniak B, Woźniak A, SzewczykGolec K. Melatonin supplementation improves oxidative and inflammatory state in the blood of professional athletes during the preparatory period for competitions. Free Radical Res. 2019;53(2):198-209.
  9. Cardinali DP, Vigo DE. Melatonin, mitochondria, and the metabolic syndrome. Cell Mol Life Sci. 2017 Nov;74(21):3941-3954. doi: 10.1007/s00018-017-2611-0. Epub 2017 Aug 17.
  10. Al-Sarraf IAK, Kasabri V, Akour A, Naffa R. Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study. Horm Mol Biol Clin Investig. 2018 May 29;35(2). pii: /j/hmbci.2018.35.issue-2/hmbci-2018-0016/hmbci-2018-0016.xml. doi: 10.1515/hmbci-2018-0016.
  11. Anderson G, Reiter RJ. Melatonin: Roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020 May;30(3):e2109. doi: 10.1002/rmv.2109. Epub 2020 Apr 21. PMID: 32314850; PMCID: PMC7235470.
  12. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020 Jun 1;250:117583. doi: 10.1016/j.lfs.2020.117583. Epub 2020 Mar 23. PMID: 32217117; PMCID: PMC7102583.
  13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097.
  14. Balshem H et al. Grade guidelines: 3 ratng the quality of evidence. Journal of Clinical Epidemiology, Maryland Heights, v. 64, n. 4, p. 401-406, 2011
  15. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
  16. Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol. 2019 Feb;15(2):105-125. doi: 10.1038/s41574-018-0130-1.
  17. Boga JA, Caballero B, Potes Y, Perez-Martinez Z, Reiter RJ, Vega-Naredo I, Coto-Montes A. Therapeutic potential of melatonin related to its role as an autophagy regulator: A review. J Pineal Res. 2019 Jan;66(1):e12534. doi: 10.1111/jpi.12534. Epub 2018 Nov 26.
  18. Forrestel AC, Miedlich SU, Yurcheshen M, Wittlin SD, Sellix MT. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2017 May;60(5):808-822. doi: 10.1007/s00125-016-4175-1. Epub 2016 Dec 16.
  19. Challet E. Keeping circadian time with hormones. Diabetes Obes Metab. 2015 Sep;17 Suppl 1:76-83. doi: 10.1111/dom.12516.
  20. Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, Cui N, Middleton B, Ackermann K, Kayser M, Thumser AE, Raynaud FI, Skene DJ. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10761-6. doi: 10.1073/pnas.1402663111. Epub 2014 Jul 7.
  21. Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv 2020. 10.1101/2020.10.15.20213546. [Epub ahead of print: 18 Oct 2020.
  22. García JA, Volt H, Venegas C, et al. . Disruption of the NF-ΰB/NLRP3 connection by melatonin requires retinoid-related orphan receptor-α and blocks the septic response in mice. Faseb J 2015;29:3863–75. 10.1096/fj.15-273656.
  23. Hardeland R. Melatonin and inflammation-Story of a double-edged blade. J Pineal Res 2018;65:e12525. 10.1111/jpi.12525.
  24. Jung K-A, Kwak M-K. The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 2010;15:7266–91. 10.3390/molecules15107266.
  25. DiNicolantonio JJ, McCarty M, Barroso-Aranda J. Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections. Open Heart. 2021 Mar;8(1):e001568. doi: 10.1136/openhrt-2020-001568. PMID: 33741691; PMCID: PMC7985934.
  26. Zhou Y, Hou Y, Shen J, et al. . A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol 2020;18:e3000970. 10.1371/journal.pbio.3000970.
  27. Patel VB, Zhong J-C, Grant MB, et al. . Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 2016;118:1313–26. 10.1161/CIRCRESAHA.116.307708.
  28. McLachlan CS. The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms. Clin Hypertens 2020;26:14. 10.1186/s40885-020-00147-x.
  29. Hasan ZT, Atrakji DMQYMAA, Mehuaiden DAK. The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients. Int J Infect Dis. 2022 Jan;114:79-84. doi: 10.1016/j.ijid.2021.10.012. Epub 2021 Oct 12. PMID: 34653660; PMCID: PMC8506572.
  30. Mousavi SA, Heydari K, Mehravaran H, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Shamshirian A. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J Med Virol. 2022 Jan;94(1):263-271. doi: 10.1002/jmv.27312. Epub 2021 Sep 8. PMID: 34460132; PMCID: PMC8662261.
  31. Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, Saeedi-Boroujeni A, Rezaie E, Ghaleh HEG, Aghamollaei H, Fasihi-Ramandi M, Hassanpour K, Alishiri G. Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial. Arch Med Res. 2022 Jan;53(1):79-85. doi: 10.1016/j.arcmed.2021.06.006. Epub 2021 Jun 23. PMID: 34229896; PMCID: PMC8220995.
  32. Bologna C, Madonna P, Pone E. Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study. J Clin Med. 2021 Dec 14;10(24):5857. doi: 10.3390/jcm10245857. PMID: 34945156; PMCID: PMC8705392.
  33. Zhou Y, Hou Y, Shen J, Mehra R, Kallianpur A, Culver DA, Gack MU, Farha S, Zein J, Comhair S, Fiocchi C, Stappenbeck T, Chan T, Eng C, Jung JU, Jehi L, Erzurum S, Cheng F. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol. 2020 Nov 6;18(11):e3000970. doi: 10.1371/journal.pbio.3000970. PMID: 33156843; PMCID: PMC7728249.

How to Cite

Chaves, M. T., & Chaves, A. P. T. (2022). Major clinical outcomes of melatonin use in COVID-19 patients: a systematic review. International Journal of Nutrology, 15(2). https://doi.org/10.54448/ijn22208